Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H23N7O6 |
Molecular Weight | 457.4399 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CN(CN1C3=C(NC2)NC(N)=NC3=O)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(O)=O)C(O)=O
InChI
InChIKey=QYNUQALWYRSVHF-OLZOCXBDSA-N
InChI=1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12-,13+/m1/s1
METHYLENETETRAHYDROFOLIC ACID, L-(+), an endogenous biomodulator that was developed under the brand name modufolin or arfolitixorin by the Isofol Medical. Arfolitixorin is developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. This drug is currently being studied in a global phase 3 clinical trial. Besides, the drug successfully completed phase II as rescue therapy for osteosarcoma. 21 May 2019 Isofol Medical has received clinical patent protection for the arfolitixorinin USA. It relates to a method of increasing blood concentration of deoxyuridine, a blood biomarker for inhibition of tumor growth in human cancer treatment.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02244632
IV injection every second week for 8 weeks 30 to 240 mg/m2
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
189304
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID60185584
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY | |||
|
1989
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY | |||
|
DB12676
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY | |||
|
10689
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY | |||
|
100000178228
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY | |||
|
FG-126
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY | |||
|
C157079
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY | |||
|
Z8R4A37V9Q
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY | |||
|
31690-11-6
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY | |||
|
135398645
Created by
admin on Sat Dec 16 05:58:02 GMT 2023 , Edited by admin on Sat Dec 16 05:58:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)